{
  "docId": "019dd923-622c-750b-8b9d-5bbf2c91b5c4",
  "docSlug": "839c06ad1c27",
  "documentTitle": "Valeant Pharmaceuticals International (VRX)",
  "authorId": "52_Citron_Research",
  "authorName": "Citron Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2015-10-21 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 1,
  "pageCount": 8,
  "prevPage": null,
  "nextPage": 2,
  "slideType": "executive_summary",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "This is a classic short-seller research note designed to frame a company as a fraud (Enron comparison).",
  "elementsJson": [
    "paragraph",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": "https://imgproxy.kitesheet.com/gEYK1m4wSpmoesGpo9HP41Nntdtc8IFt3tTooD-KQl8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MzljMDZhZDFjMjcvcDAwMS5wbmc",
  "slideHref": "/slides/019dd923-622c-750b-8b9d-5bbf2c91b5c4/1",
  "deckHref": "/decks/019dd923-622c-750b-8b9d-5bbf2c91b5c4",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9d-5bbf2c91b5c4.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9d-5bbf2c91b5c4#slide-1",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Valeant: Could this be the Pharmaceutical Enron?",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-14d8-75c0-8c92-78852cfbee60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "price target: $50",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-14d8-75c0-8c92-7dd49f5f98e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "With its quarterly earnings report scheduled for first thing Monday morning, Valeant was well aware of the scrutiny that was about to come down on Philidor and the R&O lawsuit, as both SIRF and the NYT had contacted management. Valeant came prepared for the conference call with pre-written questions and answers -- one about Philidor, and one about R&O -- in its slide deck. This is where the cover up begins.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "620c8e4b-b2ad-48de-9fc8-7f2217540ba1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.78,
        "x": 0.11,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "On Monday morning before earnings, a report came out of SIRF, uncovering undisclosed relationships with specialty pharmas, namely Philidor RX. Most importantly, the article introduced Wall Street to a court filing made by a company called R&O Pharmacy, filed with the California District Court in September, in which this small regional pharmacy claims it had received an improper demand for payment from Valeant to the tune of $69 million.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6db2f96f-5211-4324-b52b-bfd35cf7e756",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "Just four days ago in the world of Valeant, no one had ever heard of Philidor RX. Recent concerns about the company focused on its unsavory business practices of massive prices raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development. But no one had discussed how these drugs were distributed....until this week.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74ebe42b-f17c-4f66-bfb4-d40d1f4fa273",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Just yesterday, the New York Times increased its scrutiny on Philidor by questioning if its operation was the target of subpoenas recently served on Valeant over its pricing strategy, covered the prior week.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed8a50f6-06d6-4b5d-aa08-72ed5447501b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.2,
        "y": 0.23
      },
      "kind": "title",
      "text": "Citron Publishes the Smoking Gun!! Price Target lowered to $50",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a0f580e-10c1-4f39-b37e-c017911541b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.15,
        "y": 0.19
      },
      "kind": "title",
      "text": "Valeant: Could this be the Pharmaceutical Enron?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36537c45-a56b-4b39-bfef-f973a6c6f3ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.67
      },
      "kind": "title",
      "text": "This is Not Where the Story Ends; it is Where the Story Begins",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee5cbcad-13be-4f4c-8dee-492e6c9f9220",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "60026a5d-49de-43c3-8de7-7a4ad08a65f1",
      "evidence": "The slide explicitly frames the company as a 'Pharmaceutical Enron' and alleges a 'cover up'.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 1,
      "from": 1,
      "beatId": "84bf320e-4e89-448a-95ed-196717c0f56a",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Hook",
      "beatSlug": "hook",
      "evidence": "The document begins with a provocative statement, 'Valeant: Could this be the Pharmaceutical Enron?'",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": "https://imgproxy.kitesheet.com/toWRJXQsdrxCWo0rzofGjeXjheRfszUvFXXgzAMFU9Q/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MzljMDZhZDFjMjcvcDAwMS5qcGc",
  "thumbSrc": "https://imgproxy.kitesheet.com/_W2SlpS2_FgywQofi8YIHvtg64Xnf4Zog62P9gYmIkY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MzljMDZhZDFjMjcvcDAwMS5wbmc",
  "thumbSrcAlt": "https://imgproxy.kitesheet.com/gPgFzqejGFwfwlmbAzgKBbyVkP2-2WHLIDX3wPU7m4Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MzljMDZhZDFjMjcvcDAwMS5qcGc"
}